SEC Form 4 · accession 0001209191-17-049449
Atara Biotherapeutics, Inc. · ATRA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John McGrath
Officer — EVP & Chief Financial Officer
Period of report
Aug 15, 2017
Accepted (ET)
Aug 17, 2017 · 5:36 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001604464
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 15, 2017 | M | 7,697 | $0.00 | A | 125,157 | D | |
| Common StockF3 | Aug 15, 2017 | S | 2,100 | $14.23 | D | 123,057 | D | |
| Common StockF4 | Aug 16, 2017 | S | 2,100 | $14.39 | D | 120,957 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF8,F5,F6,F7 | — | Aug 15, 2017 | M | 7,697 | D | — | — | Common Stock | 7,697 | 12,829 | I |
Explanation of responses
- F1Shares issued upon settlement of vested restricted stock units ("RSUs").
- F2Transaction pursuant to Rule 10b5-1 Plan adopted July 6, 2016.
- F3The price in Column 4 is a weighted average sale price. The prices actually received ranged from $14.20 to $14.275. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F4The price in Column 4 is a weighted average sale price. The prices actually received ranged from $14.05 to $14.60. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F5Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement.
- F6The RSUs were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in order for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the "IPO"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through May 15, 2015, were settled on May 15, 2015. The service-based vesting condition provides that 25% of the total number of shares on January 6, 2015 and 1/48th of the total number of shares monthly thereafter, subject to the holder's continuous service through each such date.
- F7The earlier of (i) December 12, 2020 or (ii) the recipient's termination date.
- F8The shares are held by the David B. Horowitz and John McGrath Jr. Revocable Living Trust dated 6/3/11, of which the Reporting Person is trustee.